© 1995 by Oxford University Press
Journal of the National Cancer Institute, Vol. 87, No. 7, 524-531,
April 5, 1995
© 1995 Oxford University Press
Bladder and Kidney Cancer Following Cyclophosphamide Therapy for Non-Hodgkin's Lymphoma
Epidemiology and Biostatistics Program, Division of Cancer Etiology, National Cancer Institute Bethesda, Md
University Hospital Uppsala, Sweden
The Ontario Cancer Treatment and Research Foundation Toronto, Canada
The Netherlands Cancer Institute Amsterdam
The University of Iowa Iowa City
The Dr. Daniel den Hoed Cancer Center Roterdam, The Netherlands
The University of Texas M. D. Anderson Cancer Center Houston
University of Texas Health Sciences Center San Antonio
Princess Margaret Hospital Toronto
Correspondence to: Lois B. Travis, M.D., National Institutes of Health, Executive Plaza North, Suite 408, Bethesda, MD 20892
BACKGROUND:: Cyclophosphamide is an established bladder carcinogen, but few studies have examined the relationship between dose and effect. The largest analysis to date included only seven cases of bladder cancer. No investigation has estimated the risk of kidney cancer. Purpose: The purpose of this study was to quantify the risk of bladder and kidney cancer following cyclophosphamide therapy.
METHODS:: Within a cohort of 6171 two-years survivors of non-Hodgkin's lymphoma (NHL), 48 patients with secondary cancer of the urinary tract were identified and matched to 136 control subjects with NHL who did not develop a second malignancy. Detailed information on chemotherapeutic drugs and cumulative dose received was collected for all subjects. Radiation dose to the target organ was estimated from individual radiotherapy records. Evaluations of the risk of second cancer as a result of treatment with cyclophosphamide alone, radiation alone, or both therapies were made relative to those patients who were exposed to neither treatment modality.
RESULTS:: A significant 4.5-fold risk of bladder cancer (95% confidence interval[CI] = 1.5–13.6) followed therapy with cyclophosphamide, and risk was dependent upon cumulative dose. Among patients who received a total amount of cyclophosphamide of less than 20 g, a nonsignificant 2.4-fold risk of bladder cancer was apparent. Significantly elevated sixfold (95% CI = 1.3–29) and 14.5-fold (95% CI = 2.3–94) risks of bladder malignancy followed cumulative doses of 20–49 g and 50 g or more, respectively (P value for trend =.004). Radiotherapy given without cyclophosphamide was associated with a nonsignificant increased risk of bladder malignancy. Excess bladder cancer risk following treatment with both radiotherapy and cyclophosphamide was as expected if individual risks were summed. Neither radiotherapy nor cyclophosphamide was associated with excesses of kidney cancer.
CONCLUSIONS:: Cyclophosphamide-related bladder cancer is dose dependent. For patients given cumulative doses between 20 and 49 g, the absolute risk of bladder cancer is on the order of three excess cancers per 100 NHL patients after 15 years of follow-up. At cumulative doses of 50 g or more, the excess risk increases to approximately seven excess bladder cancers per 100 NHL patients. Implications: The strong dose-response relationship and high absolute risk of bladder cancer underscore the importance of limiting the cumulative dose of cyclophosphamide to what is required to achieve therapeutic end points. The risk of secondary bladder malignancy and other late sequelae of therapy must be carefully weighed against the curative gains provided by cyclophosphamide.Moreover, long-term side effects of therapy that might be acceptable in cancer treatment may need to be re-evaluated for patients with non-neoplastic disorders. (J Natl Cancer Inst 87; 524–530, 1995)
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Eriguchi, H. Oka, T. Mizobuchi, T. Kamimura, K. Sugawara, and A. Harada Long-term outcomes of idiopathic membranous nephropathy in Japanese patients treated with low-dose cyclophosphamide and prednisolone Nephrol. Dial. Transplant., October 1, 2009; 24(10): 3082 - 3088. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. C. Bluhm, C. Ronckers, R. J. Hayashi, J. P. Neglia, A. C. Mertens, M. Stovall, A. T. Meadows, P. A. Mitby, J. A. Whitton, S. Hammond, et al. Cause-specific mortality and second cancer incidence after non-Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study Blood, April 15, 2008; 111(8): 4014 - 4021. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Bernatsky, L Joseph, J-F Boivin, C Gordon, M Urowitz, D Gladman, P R Fortin, E Ginzler, S-C Bae, S Barr, et al. The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study Ann Rheum Dis, January 1, 2008; 67(1): 74 - 79. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Maule, G. Scelo, G. Pastore, P. Brennan, K. Hemminki, E. Tracey, R. Sankila, E. Weiderpass, J. H. Olsen, M. L. McBride, et al. Risk of Second Malignant Neoplasms After Childhood Leukemia and Lymphoma: An International Study J Natl Cancer Inst, May 16, 2007; 99(10): 790 - 800. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. B. Travis The Epidemiology of Second Primary Cancers Cancer Epidemiol. Biomarkers Prev., November 1, 2006; 15(11): 2020 - 2026. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Y. Mudie, A. J. Swerdlow, C. D. Higgins, P. Smith, Z. Qiao, B. W. Hancock, P. J. Hoskin, and D. C. Linch Risk of Second Malignancy After Non-Hodgkin's Lymphoma: A British Cohort Study J. Clin. Oncol., April 1, 2006; 24(10): 1568 - 1574. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. D. Ryan, M. Harisinghani, M. F. Lerwill, and D. S. Kaufman Case records of the Massachusetts General Hospital. Case 6-2006. A 71-year-old woman with urinary incontinence and a mass in the bladder. N. Engl. J. Med., February 23, 2006; 354(8): 850 - 856. [Full Text] [PDF]
|
|
|
|
|
|
A Knight, J Askling, F Granath, P Sparen, and A Ekbom Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide Ann Rheum Dis, October 1, 2004; 63(10): 1307 - 1311. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. W. G. du Buf-Vereijken, A. J. W. Branten, and J. F. M. Wetzels Cytotoxic therapy for membranous nephropathy and renal insufficiency: improved renal survival but high relapse rate Nephrol. Dial. Transplant., May 1, 2004; 19(5): 1142 - 1148. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Andre, N. Mounier, X. Leleu, A. Sonet, P. Brice, M. Henry-Amar, H. Tilly, B. Coiffier, A. Bosly, P. Morel, et al. Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients Blood, February 15, 2004; 103(4): 1222 - 1228. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Kattlove and R. J. Winn Ongoing Care of Patients After Primary Treatment for Their Cancer CA Cancer J Clin, May 1, 2003; 53(3): 172 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Dores, C. Metayer, R. E. Curtis, C. F. Lynch, E. A. Clarke, B. Glimelius, H. Storm, E. Pukkala, F. E. van Leeuwen, E. J. Holowaty, et al. Second Malignant Neoplasms Among Long-Term Survivors of Hodgkin's Disease: A Population-Based Evaluation Over 25 Years J. Clin. Oncol., August 15, 2002; 20(16): 3484 - 3494. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. E. Witzig, I. W. Flinn, L. I. Gordon, C. Emmanouilides, M. S. Czuczman, M. N. Saleh, L. Cripe, G. Wiseman, T. Olejnik, P. S. Multani, et al. Treatment With Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Rituximab-Refractory Follicular Non-Hodgkin's Lymphoma J. Clin. Oncol., August 1, 2002; 20(15): 3262 - 3269. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. P. Petros, G. Broadwater, D. Berry, R. B. Jones, J. J. Vredenburgh, C. J. Gilbert, J. P. Gibbs, O. M. Colvin, and W. P. Peters Association of High-dose Cyclophosphamide, Cisplatin, and Carmustine Pharmacokinetics with Survival, Toxicity, and Dosing Weight in Patients with Primary Breast Cancer Clin. Cancer Res., March 1, 2002; 8(3): 698 - 705. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Barista, F. Cabanillas, J. E. Romaguera, I. F. Khouri, Y. Yang, T. L. Smith, S. S. Strom, L. J. Medeiros, and F. B. Hagemeister Is there an increased rate of additional malignancies in patients with mantle cell lymphoma? Ann. Onc., February 20, 2002; 13(2): 318 - 322. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. B. Travis, M. Gospodarowicz, R. E. Curtis, E. Aileen Clarke, M. Andersson, B. Glimelius, T. Joensuu, C. F. Lynch, F. E. van Leeuwen, E. Holowaty, et al. Lung Cancer Following Chemotherapy and Radiotherapy for Hodgkin's Disease J Natl Cancer Inst, February 6, 2002; 94(3): 182 - 192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H M Coutinho, J W Groothoff, M Offringa, M P Gruppen, and H S A Heymans De novo malignancy after paediatric renal replacement therapy Arch. Dis. Child., December 1, 2001; 85(6): 478 - 483. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hisada, R. J. Biggar, M. H. Greene, J. F. Fraumeni Jr, and L. B. Travis Solid tumors after chronic lymphocytic leukemia Blood, September 15, 2001; 98(6): 1979 - 1981. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. B. Travis, M. Andersson, M. Gospodarowicz, F. E. van Leeuwen, K. Bergfeldt, C. F. Lynch, R. E. Curtis, B. A. Kohler, T. Wiklund, H. Storm, et al. Treatment-Associated Leukemia Following Testicular Cancer J Natl Cancer Inst, July 19, 2000; 92(14): 1165 - 1171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. C. Smith, A. E. Welch, A. W. Hutcheon, I. D. Miller, S. Payne, F. Chilcott, S. Waikar, T. Whitaker, A. K. Ah-See, O. Eremin, et al. Positron Emission Tomography Using [18F]-Fluorodeoxy-D-Glucose to Predict the Pathologic Response of Breast Cancer to Primary Chemotherapy J. Clin. Oncol., April 1, 2000; 18(8): 1676 - 1688. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Hunninghake Statement on Sarcoidosis Am. J. Respir. Crit. Care Med., August 1, 1999; 160(2): 736 - 755. [Full Text]
|
|